Members of the Association of Cancer Patients and Relatives (APACFA) held a demonstration in front of the National Cancer Institute (INCAN) demanding the replacement of three oncology drugs.
“Our claim goes through the bidding processes because, although INCAN is conducting the bidding, it is quite extensive and very cumbersome,” said Juana Moreno, secretary of APACFA, in a chat with Informal Mornings through Unión TV. For this reason, she commented that they request the modification of Law 2051, of Public Procurement.
The Union reported that the claimed drugs are enzalutamide, to treat prostate cancer; dacarbacin, against melanomas and lymphomas; and pembrolizumab, a so-called monoclonal antibody that is used against different types of cancer.
